Pediatric liver transplantation

Progress in Transplantation

Volumn 12, Issue 2, 2002, Pages 136-156

  Jaskowski Phillips, Susan K ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VARICELLA ZOSTER VACCINE;

CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TRANSPLANTATION; NURSING; PATIENT MONITORING; PEDIATRIC SURGERY; PLASMAPHERESIS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; REVIEW; SIDE EFFECT; STOMACH ULCER; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0036095620     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.12.2.q141p116m0q7667v     Document Type: Review

References (134)

1. Homotransplantation of the liver in humans
2. Pediatric liver transplantation
3. Advances in pediatric liver and intestinal transplantation
4. Indications for pediatric liver transplantation
5. Indications for pediatric liver transplantation
6. Choosing a pediatric recipient for orthotopic liver transplantation
7. Liver transplantation in children
8. Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation: A review
9. Orthotopic liver transplantation for congenital biliary atresia. An 11-year, single-center experience
10. Pediatric issues in solid organ transplantation
11. Hereditary tyrosinemia type 1 - An overview
12. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia
13. Liver transplantation for hereditary tyrosinemia - Early transplantation following the patient's stabilization
14. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure
15. Liver transplantation for fulminant hepatic failure
16. Early indicators of prognosis in fulminant hepatic failure
17. Liver transplantation for neonatal hepatitis as compared to the other two leading indications for liver transplantation in children
18. Primary liver cell carcinoma associated with biliary cirrhosis due to congenital bile duct atresia
19. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence
20. Morbidity and mortality related to home parenteral nutrition in patients with gut failure
21. Syndromic paucity of interlobular bile duct (Alagille syndrome or arteriohepatic dysplagia): Review of 80 cases
22. Biliary atresia associated with congenital structural anomalies
23. Parental psychosocial outcomes in pediatric liver and/or intestinal transplantation: Pretransplantation and the early postoperative period
24. Pediatric liver transplantation
25. Extended preservation of the liver for clinical transplantation
26. Extended preservation of the human liver grafts with UW solution
27. Incidence and risk factors of prolonged mechanical ventilation and causes of reintubation after liver transplantation
28. Intensive care management after pediatric liver transplantation: A single-center experience
29. Liver transplantation
30. Liver transplantation therapy in children: Part II
31. Immunosuppression in organ transplantation
32. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients
33. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection
34. Comparitive longterm evaluation of tacrolimus and cyclosporine in pediatric liver transplantation
35. Reasons why some children receiving tacrolimus therapy require steroids more than 5 years post liver transplantation
36. Cyclosporine immunosuppression
37. Experience in 1000 liver transplants under cyclosporine-steroid therapy: A survival report
38. Cyclosporine
39. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients
40. 10 Years of pediatric liver transplantation
41. Sirolimus: A potent new immunosuppressant for liver transplantation
42. Sirolimus-tacrolimus combination immunosuppression
43. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus
44. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus
45. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
46. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
47. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation
48. The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection
49. Use of Thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation
50. Is sequential use of ALG and OKT 3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?
51. OKT3 in allogeneic transplantation: Clinical efficacy, mode of action and side effects
52. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipient
53. Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients
54. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
55. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
56. Risk factors and outcomes after pediatric liver transplantation
57. Critical complications of liver transplantation
58. Early complications after orthotopic liver transplantation
59. Bleeding and coagulation abnormalities in alcoholoic cirrhotic liver disease
60. Splenic artery aneurysm and orthotopic liver transplantation
61. Treatment of multiple aneurysms of the splenic artery after liver transplantation by percutaneous embolization and laparoscopic splenectomy
62. Infant pediatric liver transplantation results equal those for older pediatric patients
63. Long-term results of pediatric liver transplantation: An analysis of 569 transplants
64. Surgical complications and long-term outcome in pediatric liver transplantation
65. Changes in coagulation
66. Raised hematocrit - A contributing factor to hepatic artery thrombosis following liver transplantation
67. Protein C deficiency and portal thrombosis in liver transplantation in children
68. Doppler ultrasound of the hepatic artery and vein performed daily in the first two weeks after orthotopic liver transplantation. Useful for the diagnosis of acute rejection?
69. Sinusoidal living cell damage: The critical injury in cold preservation of liver allograft in the rat
70. Is hepatic artery thrombosis after liver transplantation really a surgical complication?
71. A hypercoagulable state follows orthotopic liver transplantation
72. Hepatic artery thrombosis after pediatric liver transplantation - A medical or surgical event?
73. Hepatic artery thrombosis due to acute pancreatitis following liver transplantation
74. Hepatic artery stenosis and thrombosis in transplant recipients: Doppler diagnosis with resistive index and systolic acceleration time
75. Imaging in liver transplantation
76. Hyperbaric oxygen therapy for hepatic artery thrombosis after liver transplantation in children
77. Liver transplantation in children
78. Complications of venous reconstruction in human orthotopic liver transplantation
79. Distal splenorenal shunt for portal vein thrombosis after liver transplantation
80. The successful management of portal vein thrombosis after hepatic transplantation with the splenorenal shunt
81. The management of T-tube leaks in orthotopic liver transplant recipients with endoscopically placed nasobiliary catheters
82. The incidence and management of biliary complications following liver transplantation in children
83. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation
84. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. multicenter trial
85. Is hepatic histology the true gold standard in diagnosing acute hepatic allograft rejection?
86. Acute cellular rejection after liver transplantation: Variability, morbidity, and mortality
87. FK506 rescue therapy in liver transplant recipients with drug-resistant rejection
88. FK506 rescue therapy for resistant rejection episodes in liver transplant recipients
89. Use of FK506 for treatment of chronic rejection after liver transplantation
90. FK506 conversion for intractable rejection of the liver allograft
91. The treatment of intractable rejection with FK506 in pediatric liver transplant recipients
92. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation
93. Infections in solid organ transplant recipients
94. Infection and associated risk factors in the immediate postoperative period of pediatric liver transplantation: A study of 176 transplants
95. Postoperative infectious complications in paediatric liver transplantation: A study of 48 transplants
96. Infected bile lakes following pediatric liver transplantation: Nonsurgical management
97. Pediatric liver transplantation: Patient evaluation and selection, infectious complications, and life-style after transplantation
98. Infectious complications in liver transplantation
99. Pediatric liver transplantation at UCLA
100. Pediatric liver transplantation: The Dallas experience
101. Infectious complications of solidorgan transplantation in children
102. Candida infection in pediatric liver transplant recipients
103. Aspergillosis in liver transplantation
104. Infections with cytomegalovirus and 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies
105. Quantitative PCR determination of human cytomegalovirus in blood cells
106. Cytomegalovirus infection in pediatric liver recipients: A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment
107. Severe cytomegalovirus infection and immunosuppressive therapy in pediatric liver transplantation
108. Good and impaired response to ganciclovir treatment of severe CMV infections in liver transplant recipients
109. Cytomegalovirus infection in living related liver transplantation: Rapid diagnosis by human monoclonal antibody staining of blood leucocytes
110. Clinical patterns of cytomegalovirus disease after liver transplantation
111. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children
112. Epstein-Barr virus, cytomegalovirus and other virus infections in children after transplantation
113. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disease in young children on FK506 after liver transplantation
114. Posttransplant lymphoproliferative disease in pediatric liver transplantation: Interplay between primary Epstein-Barr virus infection and immunosuppression
115. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus
116. The effects of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients
117. The involvement of the gastrointestinal tract in posttransplant lymphoproliferative disease in pediatric liver transplantation
118. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation
119. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for post-transplant lymphoproliferative disease
120. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients
121. Management of post-transplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
122. Infections in pediatric orthotopic heart transplant recipients
123. Clinical manifestations of herpesvirus infections in pediatric renal transplant recipients
124. Viral complications of OKT3 monoclonal antibody in children undergoing renal transplantation
125. Role of parvovirus B19 in human disease
126. Occurrence and clinical role of active parvovirus B19 infection in transplant recipients
127. Adenovirus infection in pediatric liver transplant recipients
128. Childhood vaccination against varicella: Persistence of antibody, duration of protection, and vaccine efficacy
129. Response to varicella immunization in pediatric liver transplant recipients
130. Varicella vaccine in children requiring renal or hepatic transplantation
131. Varicella-zoster infection in pediatric solid-organ transplant recipients: A hospital-based study in the prevaricella vaccine era